MarginsXMarginsX
Home › Markets › Health Care › LTRN

Lantern Pharma Inc. (LTRN)

LTRN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3890
-10.18% on the day
Market cap
$5.8M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerLTRN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001763950
SEC industry codePharmaceutical Preparations
Incorporated inTX

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
5.7 months
$6.7M cash at June 30, 2026
Share count, 1 year
+18.4%
2025-08-08 to 2026-08-10 · +17.6% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$100K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"For this reason, there is substantial doubt about the Company's ability to continue as a going concern in the absence of obtaining substantial additional funding."
10-Q 2026-08-14
Cash and burn$6.7M cash; operating cash flow -$3.5M a quarter.Report 2026-06-30
Shares outstanding12,784,146 (2026-08-10); 10,799,417 a year earlier; 10,869,040 three years earlier.Cover page 2026-08-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-09-30
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-10-01
AuditorEisnerAmper LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $100K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$7.1M-$2.9M$6.7MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$3.3M-$3.8M$4.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$4.1M-$2.8M$4.4MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$4.2M-$4.6M$8.4MNo debt tagsNeeds four quarters10-Q 2025-11-12
Q2 2025
2025-06-30
Not filed-$4.3M-$3.9M$6.1MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$4.5M-$4.4M$6.4MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$5.9M-$4.0M$7.5MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$4.5M-$5.6M$8.1MNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-30
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-08-14
Latest current report8-K2026-10-01
Latest proxyDEF 14A2026-10-19

Source: SEC EDGAR submissions feed, 263 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-23.8%
1 month-39.1%
3 months-83.5%
Year to date-85.7%
1 year-87.5%
From 52-week high-89.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
APREAprea Therapeutics Inc.$0.4063-2.38%$5.8M
BLRXBioLineRx Ltd.$1.15-12.61%$5.7M
ALZNAlzamend Neuro Inc.$1.18-4.84%$5.7M
ACXPAcurx Pharmaceuticals Inc.$0.9350-2.60%$5.7M
FBLGFibroBiologics Inc.$0.9034-2.00%$6.1M
TOVXTheriva Biologics Inc.$0.1400-2.85%$6.4M
ENVBEnveric Biosciences Inc.$1.44-4.95%$6.4M
ADXNAddex Therapeutics Ltd$3.83-5.67%$6.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier